⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplementary Method 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial

Xun Cao Zhuo-Ying Luo Han-Ying Huang Jiayu Zhou Xi Chen Yingying Huang Liang‐Ru Ke Lujun Han Yue Xue Xia Wei‐Xiong Xia Lin‐Quan Tang Shan-Shan Guo Xiang Guo Xing Lv

View Full Paper

Ask AI

Bookmark

Share

Key Points

Capecitabine maintenance therapy can be effective in patients with residual nasopharyngeal carcinoma.
Radiological diagnostic criteria were established to assess residual disease accurately.
The single-arm trial involved multiple patients undergoing treatment, monitoring effectiveness.
Findings may influence future therapeutic strategies for nasopharyngeal carcinoma management.

Implication

Phase II trial evaluates maintenance therapy in patients with residual nasopharyngeal carcinoma, suggesting radiological criteria for assessment.

Abstract

Supplementary Method 1. Radiological diagnostic criteria of residual nasopharyngeal carcinoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01b8 https://doi.org/10.1158/1078-0432.29760479

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Method 2 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2025
2Supplementary Figure 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2025
3Supplementary Data 1 from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2025
4Data from Capecitabine Maintenance Therapy in Patients with Residual Nasopharyngeal Carcinoma: A Single-Arm, Phase II Trial2025
5Efficacy and safety of schedule-modified oral capecitabine/S-1 as maintenance therapy for stage N3 nasopharyngeal carcinoma after definitive chemoradiotherapy: a multicentre, single-arm phase II clinical trialHuman Clinical Trial · 2026